941 studies (2 from unattributed sources) on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Polaris Peptides | 26 | 99.51% | View COA → |
| Qingdao Sigma Chemical | 23 | 99.51% | View COA → |
| Peptide Sciences | 21 | 99.71% | View COA → |
| Nexaph | 18 | 98.41% | View COA → |
| Simple Peptide | 16 | 99.86% | View COA → |
| Peptide Crafters | 16 | 99.8% | View COA → |
| (unknown) | 16 | 99.57% | View COA → |
| Aminos Research | 15 | 99.73% | View COA → |
Recent certificates: #63635 (99.885%) · #62991 (99.9%) · #42777 (99.91%) · #22090 (99.8%) · #22091 (99.7%) · #14540 (99.9%)
Manufacturers with published third-party certificates of analysis for Semaglutide. Open a vendor to see every batch we've verified.
If this trial demonstrates positive effects, **oral semaglutide could offer a more comprehensive management strategy for Type 2 Diabetes**, extending beyond glycemic control to address critical postprandial metabolic …
The initiation of a Phase 2 study for **PG-102** signifies a critical step in its development as a potential new treatment for **Type 2 Diabetes Mellitus**. If **PG-102** demonstrates favorable efficacy and safety, it…
If the ASCEND PLUS trial demonstrates positive results, it could significantly **expand the indication for semaglutide as a primary cardiovascular prevention strategy** in individuals with **type 2 diabetes** who are …
Semaglutide, a GLP-1RA, indicated potential to improve 90-day functional recovery in large vessel occlusion stroke patients after endovascular thrombectomy.
If this trial demonstrates that semaglutide effectively slows **Chronic Kidney Disease progression** in **Type 2 Diabetes** patients, it could significantly alter clinical practice. **Semaglutide could become a corner…
This research is crucial for understanding the broader therapeutic potential of **GLP-1 receptor agonists** beyond their established metabolic benefits. If positive mental health effects are confirmed, it could signif…
This case highlights the critical importance of **thorough baseline liver assessment** for individuals with underlying chronic liver diseases, such as **chronic viral hepatitis**, before initiating **semaglutide** or …
This advanced human six-tissue MPS provides an unprecedented platform for dissecting complex **inter-organ communication** in metabolic health and disease. For peptide users and biohackers, understanding how drugs lik…
This research introduces a promising strategy for developing next-generation GLP-1RAs that are significantly shorter than current market leaders, potentially offering advantages in synthesis, stability, and formulatio…
**Clinicians should consider implementing extended GLP-1 RA withholding, a 24-hour clear liquid diet, and pre-procedural gastric POCUS for patients undergoing elective procedures.** This evidence suggests a shift in p…
This advanced **six-tissue microphysiological system** represents a significant step forward in preclinical drug development for **metabolic diseases**. It offers a human-relevant platform to screen anti-diabetic comp…
Research explores how genetic and non-genetic factors vary across populations to influence sleep characteristics and broader health outcomes.
Understanding patient preferences for **obesity** pharmacotherapy is paramount for enhancing treatment adherence and achieving better long-term health outcomes. **Clinicians can leverage these insights to engage in mo…
This computational identification of <b>vorinostat</b> and other LSEC-protective compounds offers a significant step forward for <b>liver fibrosis</b> research. For clinicians and researchers, it provides novel, targe…
This case underscores the critical importance of considering **syphilis** in the differential diagnosis of atypical rectal masses, even when malignancy is strongly suspected. Misdiagnosis can lead to unnecessary invas…
This regulatory post-marketing surveillance study is crucial for understanding **Ozempic's (Semaglutide)** performance in a real-world setting, especially within the Korean **Type 2 Diabetes Mellitus** population. Whi…
SEMAFOLLOW is a real-world study evaluating **semaglutide 2.4 mg** effectiveness, weight change, and well-being in patients with Grade 3 and complicated obesity.
Understanding the interaction between **omeprazole** and **oral semaglutide** is crucial for optimizing treatment protocols for **type 2 diabetes** and **obesity**. If omeprazole significantly alters semaglutide absor…
Open-label clinical trial to evaluate oral **Semaglutide** for significant fibrosis due to **NAFLD** in obese or **T2DM** patients.
Retatrutide, a GIP/GLP-1/glucagon receptor agonist, was assessed for its impact on kidney parameters in patients with type 2 diabetes mellitus (T2D) and kidney disease.
A new study is evaluating whether adding **semaglutide** to **dapagliflozin** improves outcomes for **heart failure** patients with prosthetic heart valves.
This review reinforces **semaglutide's** broad utility, extending beyond **T2DM** and **obesity** to include **MASLD**, offering a new therapeutic avenue for a complex liver condition. For peptide users and clinicians…
**Semaglutide offers a robust and effective therapeutic option for managing antipsychotic-induced weight gain**, a critical unmet need in psychiatric care. This meta-analysis provides strong evidence supporting its us…
This preclinical study suggests **semaglutide could emerge as a novel pharmacotherapy for Opioid Use Disorder (OUD)**, offering a new avenue for treatment beyond current options. The ability of semaglutide to reduce b…
This research presents a significant advancement for patients requiring long-term peptide therapies, particularly those for **Type 2 Diabetes** and **obesity**. **A single hydrogel injection could replace daily or wee…
This study provides crucial context for interpreting patient-reported outcomes in **obesity** research, highlighting that observational cohorts may represent a population with a higher baseline burden of disease and l…
Semaglutide 2.4 mg effectiveness and patient outcomes in adolescents with obesity are the focus of a real-world study addressing limited data in complex populations.
This real-world data suggests that **semaglutide can achieve substantial weight loss even at submaximal doses**, offering flexibility in treatment strategies for individuals with **obesity**. For peptide users and cli…
This economic evaluation provides crucial justification for the value of **phentermine-topiramate** and **semaglutide** in managing adolescent obesity, even at current pricing. For clinicians and policymakers, the fin…
This analysis from the `FLOW` trial reinforces that **semaglutide offers broad and consistent kidney and survival protection** for individuals with **Type 2 Diabetes** and **Chronic Kidney Disease**, regardless of the…
This validated semi-mechanistic PK model offers a powerful tool for optimizing future oral **semaglutide** formulations and understanding its behavior in diverse populations. **For peptide users and biohackers, this r…
**Understanding semaglutide's role in managing obesity in PWH could offer a crucial new therapeutic avenue**, potentially improving not only weight but also complex immune and metabolic health. If successful, this res…
A preliminary randomized controlled trial is investigating whether **semaglutide 0.25 mg** weekly improves intestinal barrier function in **SBS-IF** patients over 28 days.
Understanding the pharmacokinetic interactions of **insulin icodec** and **semaglutide** in a fixed-ratio combination like **IcoSema** is critical for advancing **Type 2 Diabetes** treatment. **This research provides …
This study provides important evidence that **oral semaglutide, at the tested dose and duration, does not significantly impact cognitive decline in individuals with early Alzheimer's disease**. For individuals explori…
This research provides compelling preclinical evidence that **semaglutide and other GLP-1R agonists may offer a direct pharmacological approach to improve lymphatic function**, potentially revolutionizing the treatmen…
This study suggests that **genotype-informed nursing strategies can personalize semaglutide treatment**, particularly for patients with `TCF7L2` CT/TT genotypes who might initially respond less favorably. By providing…
This large-scale, real-world evidence provides significant reassurance regarding the ocular safety profile of **semaglutide** concerning **neovascular age-related macular degeneration (NVAMD)**. Given previous concern…
This research offers a promising strategy to mitigate the undesirable **skeletal muscle loss** associated with GLP-1 RA therapies like semaglutide, a major concern for patients and clinicians. By combining semaglutide…
This study provides compelling preclinical evidence that **semaglutide could be a valuable non-opioid treatment for Opioid Use Disorder (OUD)**. Its once-weekly dosing schedule, compared to daily injections for other …
This research provides crucial pharmacokinetic and safety data, indicating that **cagrilintide** can be administered without dose adjustments in patients with mild, moderate, or severe renal or hepatic impairment. **T…
This study provides crucial economic evidence supporting the integration of **semaglutide for HFpEF with obesity** into healthcare systems, particularly in Germany. While semaglutide demonstrates cost-effectiveness ov…
The successful development and approval of a semaglutide biosimilar could significantly impact global healthcare by **improving access and affordability for GLP-1 receptor agonist therapies**. This would allow more in…
**Establishing the safety and tolerability of GLP-1 RAs in maintenance dialysis patients is a critical step towards expanding treatment options for a high-risk population.** Currently, these patients are largely exclu…
A prospective, non-interventional study in Sweden will assess oral semaglutide's impact on blood sugar levels in **Type 2 Diabetes** patients under routine clinical care.
**This case highlights a viable non-insulin strategy for advanced T2DM patients with cognitive impairment, offering a safer alternative to insulin.** For clinicians, it suggests that a carefully selected combination o…
Oral semaglutide **25 mg** and injectable semaglutide **2.4 mg** demonstrate comparable weight loss efficacy and safety profiles in adults with obesity, an indirect comparison confirms.
This indirect comparison provides crucial insights for clinicians and individuals managing **obesity** and **overweight**, offering a comparative view of two prominent oral GLP-1R agonists where head-to-head trials ar…
**Clinicians should be aware of potential associations between these drugs and nAMD risk**, especially when prescribing to patients with existing risk factors or early signs of macular degeneration. This study provide…
Semaglutide demonstrated robust therapeutic effects in individuals with Alcohol Use Disorder (AUD), supporting its potential as a novel treatment strategy.
Free, no account — handy when you're working with Semaglutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Create free account